(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 March 2006 (23.03.2006)

PCT

(10) International Publication Number
WO 2006/029577 A1

(51) International Patent Classification:
A61K 31/4375 (2006.01) *A61P 9/00* (2006.01)
A61P 3/06 (2006.01) *A61P 9/10* (2006.01)

(21) International Application Number:
PCT/CN2005/001489

(22) International Filing Date:
19 September 2005 (19.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
200410078150.0
17 September 2004 (17.09.2004) CN
200410095066.X
23 November 2004 (23.11.2004) CN

(71) Applicant *(for all designated States except US)*: **INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES** [CN/CN]; No.1, Tian-Tan-Xi-Li, Beijing 100050 (CN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JIANG, Jian-Dong** [CN/CN]; No.1, Tian-Tan-Xi-Li, Beijing 100050 (CN). **KONG, Wei-Jia** [CN/CN]; No.1, Tian-Tan-Xi-Li, Beijing 100050 (CN). **ZHAO, Li-Xun** [CN/CN]; No.16, Cao-Qiao-Dong Road, Room 6122, Beijing 100067 (CN). **SONG, Dan-Qing** [CN/CN]; Fang-Cheng-1-Qu Building 10, Room 1905, Feng-Tai District, Beijing 100078 (CN). **WEI, Jing** [CN/CN]; No. 604, Building 56, Qinhong Street, Qinhuai District, Nanjing, Jiangsu 210006 (CN).

(74) Agent: **CHINA SINDA INTELLECTUAL PROPERTY LIMITED**; B11th Floor Focus Place, 19 Financial Street, Xicheng District, Beijing 100032 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(48) Date of publication of this corrected version:
13 July 2006

(15) Information about Corrections:
see PCT Gazette No. 28/2006 of 13 July 2006
Previous Correction:
see PCT Gazette No. 21/2006 of 26 May 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA

(57) Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma. Additional compositions and methods are provided which employ a berberine compound or berberine related or derivative compound in combination with a second anti-hyperlipidemia agent, or a different therapeutic agent to yield more effective treatment tools against hyperlipidemia and/or cardiovascular disease, and/or dual activity therapeutic methods and formulations useful to prevent or reduce hyperlipidemia and one or more causal or related symptoms or conditions associated with hyperlipidemia in mammalian subjects.

WO 2006/029577 A1